Wedbush analyst Laura Chico raised the firm’s price target on Alto Neuroscience (ANRO) to $24 from $21 and keeps a Neutral rating on the shares. Most notable in the Q1 Alto’s results, the company initiated the Phase 2b ALTO-207 study in treatment-resistant depression subjects, the firm notes. This is consistent with prior guidance and management anticipates top-line results by the second half of 2027.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained
- Ritu Baral Reiterates Buy on Alto Neuroscience, Citing Pivotal ALTO-207 Phase 2b Trial in TRD and Strong Cash Runway Through 2029
- Alto Neuroscience Shareholders Shape Governance and Equity Plans
- Alto Neuroscience reports Q1 EPS (80c) vs (56c) last year
- Alto Neuroscience initiated with a Buy at BofA